| |
NEWS RELEASE
Aptivus (tipranavir) demonstrates potent and durable treatment response
in HIV-positive women
Boehringer Ingelheim
July 24, 2007
News
|
| |
NEWS RELEASE
Boehringer Ingelheim announces first international head-to-head trial of
Aptivus (tipranavir)
versus darunavir in treatment-experienced HIV-positive patients
Boehringer Ingelheim
July 24, 2007
News
|
| |
A WEEK-IN-REVIEW FEATURED REPORT
Effects of tipranavir/r (500/200 or 500/100 mg BID) in comparison with
lopinavir/r
(400/100 mg BID) on changes in body composition and metabolic parameters
in ARV-naïve
patients over 48 weeks
Carr A, Zajdenverg R, Workman C, et al
Abstract
|
| |
|
| |
Tipranavir/ritonavir (500/200 mg bid) demonstrated potent and durable
virologic responses
and a favourable safety profile in HIV-1 positive women
participating in RESIST
Walmsley S, Squires K, Kraft M, et al
Abstract
|
| |
Usefulness of the genotypic inhibitory quotient in HIV patients
treated with tipranavir
Morello J , García-Gascó P, Rodríguez-Novoa S , et al
Abstract
|
| |
Co-administering tipranavir/r (500/200 mg BID) and enfuvirtide (ENF) in
the RESIST studies
resulted in superior virological outcomes and a comparable safety
profile compared to regimens
containing tipranavir/r without enfuvirtide
Raffi F, Battegay M, Rusconi S, et al
Abstract
|
| |
Predicted Risk of Coronary Heart Disease with Tipranavir Exposure
Compared to Conventional PI in
the
RESIST Trial
N Friis-Møller, M Kraft, H Valdez, et al
Abstract
|
| |
POSTER
Predictors
of Response to TPV/r in Pediatric Patients: Results of
PACTG1051/BI1182.14
JC Salazar, P Cahn, M Della
Negra, et al
PDF Poster
Abstract
|
| |
Mutations Associated with Response to Boosted Tipranavir in
HIV-1-infected PI-experienced Patients
AG Marcelin, B Masquelier, D Descamps, et al
Abstract
|
| |
POSTER
Effects of Tipranavir/Ritonavir on the
Activity of Hepatic and Intestinal Cytochrome P450 3A4/5
and P-glycoprotein: Implications for Drug Interactions
M Vourvahis, J Dumond, K Patterson, et al
PDF Poster
Abstract
|
| |
POSTER
Phenotypic Susceptibility
in vitro to Amprenavir, Atazanavir, Darunavir, Lopinavir, and
Tipranavir of
HIV-2 Clinical Isolates from the French ANRS HIV-2 Cohort
t> D Desbois, G
Peytavin, S Matheron, et al
PDF Poster
Abstract
|
XVI International AIDS
Conference
|
| |
Efficacy and safety results of 48 weeks of treatment with APTIVUS
oral solution co-administered
with low dose ritonavir (APTIVUS/r) in children and teenagers (phase
I/IIa study)
J. Salazar, P. Cahn, M. Della Negra, et al
Abstract
|
| |
The non-peptidic HIV inhibitor tipranavir modulates pneumocystis in
vitro growth
Mazza F., Tronconi E., Valerio A., et al
Abstract
Impact of prior PI usage on week 48 responses to tipranavir boosted
with ritonavir (TPV/r)
Pollard R.B., Staszewski S., LeBlanc R., et al
Abstract
|
| |
Tipranavir/ritonavir is more effective against protease inhibitor
(PI)-resistant strains than
other ritonavir-boosted PI in heavily antiretroviral-experienced
HIV-infected patients
de Mendoza C., Ribera E., Barreiro P., et al
Abstract
|
| |
Success of rescue therapy with TMC114 in HIV-infected patients who
failed multiple
ritonavir-boosted protease inhibitor-based regimens
E. Poveda, F. Blanco, P. García-Gasco, A
Abstract |
|
